We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Mutant NO Gene Protects Against Malaria

By Biotechdaily staff writers
Posted on 26 Nov 2002
Researchers have found that a mutation resulting in increased production of nitric oxide protects children against two of the most severe manifestations of childhood malaria, cerebral malaria and severe malarial anemia. More...
Their finding was reported in the November 9, 2002, issue of The Lancet.

Nitric oxide (NO) is toxic to malaria parasites in vitro and protects rodents from disease in vivo. The induction and regulation of the human nitric oxide synthase type 2 (NOS2) gene, which controls synthesis of NO from its substrate L-arginine, is complex and involves sequences of up to 16 kb upstream of the gene.

An international research team studied 179 children in coastal Tanzania, with and without cerebral malaria. They found that children with a variant of NOS2 that allowed them to make greater amounts of nitric oxide were 88% less likely to develop cerebral malaria than were those without the variant. The researchers then examined DNA collected through a U.S. Centers for Disease Control study of 1,106 children in Kenya. They found that the same NOS2 variant protected the Kenyan children from severe malarial anemia as well as from cerebral malaria.

"This is a major advance in understanding how and why children get the deadliest forms of malaria,” said senior author Dr. Brice Weinberg from Duke University (Durham, NC, USA).

The authors suggest that targeted interventions to increase NO delivery or production could provide novel preventive and therapeutic strategies against these major causes of mortality in African children.




Related Links:
Duke University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Portable POCT Blood Gas Analyzer
BD100
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.